Teva says the monoclonal antibody (mAb) candidate fasinumab has “big potential” and expects to see Phase III data this year. The Israel headquartered generics firm spoke about fasinumab – the osteoarthritis pain drug – during its fourth quarter earnings call last week. CEO Kare Schultz told analysts “In novel biologics, we have a lot of different things going on. “The most exciting short-term is fasinumab that we are developing together with Regeneron and where we hope to see data this year…

Regeneron says higher Dupixent (dupilumab) sales drove an increase in manufacturing and collaboration costs in Q4. In the US, Dupixent brought in revenue of $605 million (€554 million) in the final three months of 2019, up 136% on the comparable period a year earlier. Similarly, global net sales of the drug in the fourth quarter increased to $752 million, up from $319 million in 2018. Regeneron senior vice president Marion McCourt told analysts: “We continue to see strong prescribing trends…

VGXI will make Inovio Pharmaceuticals’ investigational vaccine as part of a collaborative effort to halt the progress of the coronavirus that has recently emerged in Wuhan, China. At the time of publication, 170 people have died and almost 8,000 people infected by the novel coronavirus (2019-nCoV). Wuhan, the Chinese city where the outbreak began, is under lockdown but cases of infection have been reported across the globe, including in Australia, France, and the US. There is no specific treatment for…